Targeted Protein Degradation
Cytosolic Delivery for
Targeted Protein Degradation
TRIDENT™ is a cytosolic delivery platform designed for PROTACs, molecular glues, and emerging targeted protein degradation modalities. By improving delivery to the cytosol, TRIDENT™ is designed to support functional degradation activity and help address development barriers that limit TPD programs.
Platform Partner Value
Increase functional cytosolic delivery
Enhance target degradation and downstream biological activity
Enable or rescue TPD programs limited by intracellular delivery
SCROLL
The Challenge
Delivery Failure Limits the Potential of Many TPD Programs
Many targeted protein degradation candidates demonstrate promising biology in vitro, yet fail to achieve sufficient cytosolic delivery in vivo. Following cellular uptake, payloads may become trapped in endosomal compartments, limiting access to intracellular targets and E3 ligases. As a result, systemic exposure does not reliably translate into functional degradation activity.
Endosomal Entrapment
Internalized payloads may remain sequestered within endosomes, preventing access to the cytosol and the intracellular machinery required for target degradation.
Reduced Functional Activity
Limited cytosolic delivery can lead to weak or inconsistent target degradation despite adequate systemic exposure — a disconnect that complicates dose selection and program advancement.
Program Risk
Delivery constraints may require higher dosing, narrow the therapeutic window, and contribute to attrition — increasing cost and reducing probability of success.
The TRIDENT™ Solution
TRIDENT™ Enables Cytosolic Delivery for Functional Activity
Designed to Bridge the Gap Between Exposure and Degradation Activity
TRIDENT™ is designed to improve cytosolic delivery of degradation therapeutics, supporting the intracellular target engagement required for functional target depletion.
Enhanced Cellular Uptake
Designed to improve intracellular accumulation compared with free payload, increasing the amount of therapeutic available at the site of action.
Cytosolic Delivery
Supports release from endosomal compartments to enable access to intracellular targets and the degradation machinery required for functional activity.
Functional Degradation Activity
Designed to translate cytosolic delivery into measurable target degradation and downstream biological effects.
Platform Scope
An Enabling Platform Across TPD Modalities
TRIDENT™ is being evaluated as a cytosolic delivery solution for multiple targeted protein degradation strategies.
PROTACs
Supports the intracellular exposure required for efficient ternary complex formation and catalytic degradation of target proteins.
Molecular Glues
Supports cytosolic delivery needed to facilitate productive E3–substrate interactions and functional molecular glue activity.
Next-Generation TPD
Applicable to emerging degrader modalities where intracellular delivery remains a limiting factor, including novel bifunctional and next-generation degrader chemistries.
Evidence & Validation
Partner-Focused Validation Strategy
TRIDENT™ evaluation is designed around functional outcomes relevant to translational decision-making and technical diligence.
Cellular Uptake
Quantification of intracellular accumulation versus free payload under matched conditions.
Functional Activity
Target degradation or pathway inhibition assessed relative to matched controls and free payload.
Resistance Models
Assessment of activity in cell lines with reduced sensitivity to free payload, demonstrating the platform’s utility in challenging settings.
Translational Alignment
Correlation of intracellular exposure and cytosolic delivery with functional response, supporting confidence in translational decision-making.
Data packages are designed to support partnership evaluation and technical diligence.
Partner Opportunity
Partnership Opportunities
TRIDENT™ may be deployed to enhance existing assets, enable new targets, or support platform-level collaboration in targeted protein degradation.
Target-Specific Licensing
Delivery rights structured for defined targets or programs, enabling partners to apply TRIDENT™ to specific assets within their portfolio with clear licensing terms.
Platform Collaborations
Evaluation across multiple assets within a partner portfolio, allowing systematic assessment of TRIDENT™ as a platform-level cytosolic delivery solution.
Co-Development
Joint development of TRIDENT™-enabled candidates, combining Xelcis Bio™’s delivery expertise with partner biology and therapeutic programs.